Analyst firms · Citigroup · TMO

Citigroup TMO price target and rating history

Thermo Fisher Scientific Inc (TMO) · Industrials

Citigroup rates Thermo Fisher Scientific Inc (TMO) Buy with a $660 price target, as of its latest action on Dec 11, 2025. It has published 5 rating actions on TMO since October 2021, including 2 upgrades and 0 downgrades. Across 12 firms with a TMO price target in the last 12 months, the median target is $635. Citigroup's $660 is 4% above that.

Current rating
Buy
Price target
$660
Median target, all firms
$635
Actions on TMO
5

Citigroup price target on TMO

$715$668$62020222023202420252026
Citigroup price target on TMO, each point a stated target, October 2021 to December 2025.

Every Citigroup rating on TMO

How other firms rate TMO

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
UBSBuy$730Sep 9, 2026
CLSAOutperform$748Sep 3, 2026
BernsteinMkt Perform$520Jun 26, 2026
Piper SandlerNeutral$510Jun 11, 2026
HSBCHold$540Jun 3, 2026
Wolfe ResearchOutperform$535Jun 2, 2026
RBC Capital MarketsSector Perform$490May 15, 2026
DZ BankBuy$610Mar 27, 2026
CitigroupBuy$660Dec 11, 2025
Goldman SachsBuy$685Dec 9, 2025
KeyBanc Capital MarketsOverweight$750Dec 8, 2025
Morgan StanleyOverweight$670Dec 2, 2025

Questions about Citigroup and TMO

What is Citigroup's price target for TMO?
Citigroup's latest stated price target for Thermo Fisher Scientific Inc (TMO) is $660, from its action on Dec 11, 2025.
What is Citigroup's rating on TMO?
Citigroup rates TMO Buy, a bullish rating, as of Dec 11, 2025.
When did Citigroup last change its view on TMO?
On Dec 11, 2025, Citigroup upgrades to Buy from Neutral, price target $660.
How does Citigroup's TMO target compare with other analysts?
Across 12 firms with a TMO price target in the last 12 months, the median target is $635. Citigroup's $660 is 4% above that.

More TMO rating histories

All Citigroup ratingsTMO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.